Skip to content
Screener

Income Tax at other companies

Arvinas logo
ArvinasARVN
$100K-50.0%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$208K-82.7%
Septerna, Inc. logo
Septerna, Inc.SEPN
$337K
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$0-100%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$79K-4.8%
CYP
Cypherpunk TechnologiesCYPH
-$5.12M

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemThree Months Ended May 31, 2026Three Months Ended May 31, 2025Six Months Ended May 31, 2026Six Months Ended May 31, 2025
Total operating expenses103,24792,378201,994173,695
Loss from operations(94,204)(48,322)(186,699)(111,186)
Interest and other income, net4,3985,6189,71912,131
Loss before income taxes(89,806)(42,704)(176,980)(99,055)
Provision for (benefit from) income taxes(271)760(271)760
Net loss$(89,535)$(43,464)$(176,709)$(99,815)
Net loss per share, basic and diluted$(0.81)$(0.52)$(1.60)$(1.19)
Weighted-average number of shares outstanding, basic and diluted111,084,42383,882,477110,583,61083,723,403

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s income tax?
Nurix Therapeutics, Inc. (NRIX) reported income tax of -$271K in Q1 2026.
How has Nurix Therapeutics, Inc.'s income tax changed year-over-year?
Nurix Therapeutics, Inc.'s income tax decreased by 135.7% year-over-year, from $760K to -$271K.
What is the long-term trend for Nurix Therapeutics, Inc.'s income tax?
Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s income tax has grown at a 55.2% compound annual growth rate (CAGR), from $131K to $760K.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.

Ask your AI about Nurix Therapeutics, Inc.'s income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude